13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674712
Total reported value
$1.1B
$1.1B
40 檔
45.3%
According to the latest 13F quarterly dataset, Vivo Capital, LLC managed an equity portfolio of $1.1B at the end of Q1 2025, spanning 40 distinct U.S. exchange-listed positions.
In Q1 2025, Vivo Capital, LLC adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 53 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 42.19% | -0.82% | EXIT | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 12.10% | — | -37.01% | |
| 3 | GERN | Geron CORP | Stock-Other | 5.73% | -0.06% | — | |
| 4 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.91% | +3.63% | — | |
| 5 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.78% | — | — | |
| 6 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.52% | -5.85% | EXIT | |
| 7 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.95% | — | +2.04% | |
| 8 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.80% | +1.15% | — | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.75% | -0.27% | EXIT | |
| 10 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.54% | +0.81% | — | |
| 11 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.54% | -0.12% | +62.81% | |
| 12 | TIL | Instil Bio Inc | Stock-Other | 1.35% | +0.01% | — | |
| 13 | CMPS | Compass Pathways PLC | Stock-Other | 1.27% | -0.09% | EXIT | |
| 14 | DCTH | Delcath Systems Inc | Stock-Other | 1.26% | — | -56.09% | |
| 15 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.24% | — | — | |
| 16 | VSTM | Verastem Inc | Stock-Other | 1.23% | — | — | |
| 17 | ERAS | Erasca Inc | Stock-Other | 1.23% | -9.44% | — | |
| 18 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.20% | +0.19% | — | |
| 19 | TRML | Tourmaline Bio Inc | Stock-Other | 1.19% | — | — | |
| 20 | ABEO | Abeona Therapeutics Inc | Stock-Other | 1.16% | — | — | |
| 21 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.10% | — | — | |
| 22 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.08% | — | — | |
| 23 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.94% | +0.42% | — | |
| 24 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.89% | -2.65% | — | |
| 25 | IOBTQ | Io Biotech Inc | Stock-Other | 0.89% | — | — | |
| 26 | COGT | Cogent Biosciences Inc | Stock-Other | 0.89% | -1.35% | EXIT | |
| 27 | ✓ | Stock-Other | 0.87% | — | +14.04% | ||
| 28 | CELC | Celcuity Inc | Stock-Other | 0.82% | — | — | |
| 29 | RZLT | Rezolute Inc | Stock-Other | 0.81% | — | -24.49% | |
| 30 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.80% | -0.01% | — | |
| 31 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.75% | -0.06% | — | |
| 32 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.62% | — | -46.07% | |
| 33 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.41% | — | — | |
| 34 | SRZN | Surrozen Inc | Stock-Other | 0.40% | -0.01% | — | |
| 35 | ETNBGBP | 89bio Inc | Stock-Other | 0.36% | — | — | |
| 36 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.19% | — | — | |
| 37 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.18% | +3.04% | — | |
| 38 | ALLKGUSD | Allakos Inc | Stock-Other | 0.02% | — | -74.10% | |
| 39 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.01% | — | -92.81% | |
| 40 | DTIL | Precision Biosciences Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +11.2% | -37.01% | Trim |
| 2 | 430 | Terns Pharmaceuticals Inc | +1.1% | — | Add |
| 3 | DYN | Dyne Therapeutics Inc | +1% | — | Add |
| 4 | ACRS | Aclaris Therapeutics Inc | +0.8% | — | Add |
| 5 | OLMA | Olema Pharmaceuticals Inc | -0.8% | — | Add |
| 6 | BOLT1EUR | Bolt Biotherapeutics Inc | -2.4% | — | Trim |
| 7 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 8 | ✓ | Instil Bio, Inc. | — | EXIT | Sold out |
| 9 | ALXO | Alx Oncology Holdings Inc | — | EXIT | Sold out |
| 10 | ASND | Ascendis Pharma A/S | — | EXIT | Sold out |
| 11 | AMRSEUR | Amyris Inc | — | EXIT | Sold out |
| 12 | ULCC | Frontier Group Holdings, Inc. | — | EXIT | Sold out |
| 13 | HRMY | Harmony Biosciences Holdings | — | EXIT | Sold out |
| 14 | ✓ | — | EXIT | Sold out | |
| 15 | TARS | Tarsus Pharmaceuticals Inc | — | EXIT | Sold out |
| 16 | ✓ | Aligos Therapeutics Inc | — | EXIT | Sold out |
| 17 | 4XC1 | Kalvista Pharmaceuticals Inc | — | EXIT | Sold out |
| 18 | EPIEUR | Essa Pharma Inc | — | EXIT | Sold out |
| 19 | GERN | Geron CORP | — | NEW | New buy |
| 20 | LEGN | Legend Biotech Corp-adr | — | EXIT | Sold out |
| 21 | SVA | Sinovac Biotech Ltd. | — | EXIT | Sold out |
| 22 | OPHTEUR | Iveric Bio Inc | — | EXIT | Sold out |
| 23 | ✓ | Sierra Oncology Inc Com | — | EXIT | Sold out |
| 24 | CRNX | Crinetics Pharmaceuticals In | — | EXIT | Sold out |
| 25 | CLDX | Celldex Therapeutics Inc | — | EXIT | Sold out |
| 26 | ZLAB | Zai Lab Ltd-adr | — | EXIT | Sold out |
| 27 | IMPL1USD | Ipi Legacy Liquidation Co | — | EXIT | Sold out |
| 28 | KDMN | Kadmon Holdings Inc | — | EXIT | Sold out |
| 29 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 30 | ✓ | Avadel Pharmaceuticals PLC ADR | — | NEW | New buy |
| 31 | ✓ | Avadel Pharmaceuticals PLC ADR | — | EXIT | Sold out |
| 32 | NVAX | Novavax Inc | — | EXIT | Sold out |
| 33 | ✓ | Gracell Biotechnologies-adr | — | EXIT | Sold out |
| 34 | NKTX | Nkarta Inc | — | EXIT | Sold out |
| 35 | CLDNEUR | Eiger Biopharmaceuticals Inc | — | EXIT | Sold out |
| 36 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 37 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 38 | MREO | Mereo Biopharma Group Pl-adr | — | EXIT | Sold out |
| 39 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 40 | CRISEUR | Curis Inc | — | EXIT | Sold out |
| 41 | 290A | Chinook Therapeutics Inc | — | EXIT | Sold out |
| 42 | ARQT | Arcutis Biotherapeutics Inc | — | EXIT | Sold out |
| 43 | ORIC | Oric Pharmaceuticals Inc | — | NEW | New buy |
| 44 | ARWR | Arrowhead Pharmaceuticals In | — | EXIT | Sold out |
| 45 | KURA | Kura Oncology Inc | — | EXIT | Sold out |
| 46 | DSGN | Design Therapeutics Inc | — | EXIT | Sold out |
| 47 | VALN | Valneva Se - Adr | — | EXIT | Sold out |
| 48 | TIL | Instil Bio Inc | — | NEW | New buy |
| 49 | ZYMEUSD | Zymeworks Inc | — | EXIT | Sold out |
| 50 | CMPS | Compass Pathways PLC | — | NEW | New buy |
According to official SEC Form 13F filings, Vivo Capital, LLC reported a total U.S. public equity portfolio value of $1.1B across 40 disclosed positions in Q1 2025.
During Q1 2025, Vivo Capital, LLC's top holdings by market value included SLNOEUR (42.2%)、VRNA (12.1%)、GERN (5.7%). The largest single position, SLNOEUR, represented 42.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, VRNA, GERN) accounted for 45.3% of total reported equity market value during Q1 2025.
Top New Position Initiated
SLNOEUR
市值: $318.5M
Top Position Liquidated / Trimmed
Instil Bio, Inc.
前期市值: $241.2M
In Q1 2025, Vivo Capital, LLC made 93 total portfolio adjustments, initiating 34 new buys, adding to 4 positions, trimming 2 holdings, and fully liquidating 53 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.